Clinical trial · Interventional
Effect of Remote Ischemic Preconditioning on Lung Injury After Pulmonary Resection
Effect of Remote Ischemic Preconditioning on Lung Injury in Patients Undergoing Pulmonary Resection:a Randomised Controlled Trial
NCT01307085CI-TRIAL-00012960completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine whether ischemic preconditioning reduces lung injury in patients undergoing pulmonary resection.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Neoplasms | Lung Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| remote ischemic preconditioning | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- preconditioning
- description
- Adult patients undergoing elective pulmonary lobectomy were received a remote ischemic preconditioning group after induction of anaesthesia.
- interventionNames
- Procedure: remote ischemic preconditioning
- type
- NO_INTERVENTION
- label
- conventional
- description
- Adult patients undergoing pulmonary lobectomy were received no treatment after induction of anaesthesia.
Primary outcomes (1)
- measure
- Limb remote ischemic preconditioning has effective protection of lung injury in patients undergoing pulmonary lobectomy
- timeFrame
- June,2013
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Clinical diagnosis of pulmonary carcinoma * Must be received pulmonary lobectomy Exclusion Criteria: * Cardiac disease categorized as NYHA classes II-IV * Preoperative severe impairment of respiratory function (arterial oxygen tension (PaO2) \<60 mmHg or FEV1\<50% predicted), * Pre-existing coagulopathy or thrombocytopenia * Prior receipt of chemotherapy or radiation therapy or immunotherapy * Systemic or local active infections (either clinically defined or suggested by evidence such as elevated C-reactive protein levels, leukocytosis, or a body temperature\>38℃) * Peripheral vascular disease affecting the upper limbs * Administration of vitamins, nonsteroidal anti-inflammatory agent or corticosteroid within 3 months.
References
Publications (0)
Data not yet available
No reference posted for this study.